Efficacy and Safety of HD-6277, a Novel G Protein-Coupled Receptor 40 Agonist, in Individuals with Type 2 Diabetes Mellitus: a Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Clinical Trial
HD-6277 at 50 and 100 mg improved glycemic control and was well-tolerated in adults with T2DM inadequately managed with diet and exercise. GPR40 agonists may offer a promising new therapeutic option for T2DM.
Authors
- Jun Sung Moon (ORCID: https://orcid.org/0000-0003-1569-3068)
- Byung‐Wan Lee (ORCID: https://orcid.org/0000-0002-9899-4992)
- Tae Nyun Kim (ORCID: https://orcid.org/0000-0001-6568-2469)
- Soo Kun Lim (ORCID: https://orcid.org/0000-0001-7589-5150)
- Jie-Eun Lee (ORCID: https://orcid.org/0000-0002-1039-5769)
- Jong Chul Won (ORCID: https://orcid.org/0000-0002-2219-4083)
- Choon Hee Chung (ORCID: https://orcid.org/0000-0003-1144-7206)
- Yong‐ho Lee (ORCID: https://orcid.org/0000-0002-6219-4942)
- Kyung Wan Min
- Jae Myung Yu
- Chul Woo Ahn
- Jun Hwa Hong
Institutions
- Inje University (KR)
- Yonsei University (KR)
- Eulji University (KR)
- Seoul National University Bundang Hospital (KR)
- Hallym University Kangnam Sacred Heart Hospital (KR)
- Kimpo University (KR)
- Gangnam Severance Hospital (KR)
- CHA University (KR)
- CHA University Gangnam Medical Center (KR)
- Yeungnam University College
- Yeungnam University (KR)
Publication Details
- Journal
- Diabetes & Metabolism Journal
- Published
- 2025-12-18
- DOI
- https://doi.org/10.4093/dmj.2025.0528
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00